(Q38079130)

28 August 2017

0 references

1 reference

title

Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis (English)

1 reference

28 August 2017

1 reference

hepatocellular carcinoma

1 reference

1 reference

4

1 reference

28 August 2017

Preet Paul Singh

2

0 references

author name string

Siddharth Singh

series ordinal

1

1 reference

28 August 2017

Abha Goyal Singh

series ordinal

3

1 reference

28 August 2017

William Sanchez

series ordinal

5

1 reference

28 August 2017

language of work or name

English

0 references

publication date

5 February 2013

1 reference

The American Journal of Gastroenterology

28 August 2017

published in

1 reference

28 August 2017

volume

108

1 reference

28 August 2017

issue

6

1 reference

28 August 2017

page(s)

881-91; quiz 892

1 reference

28 August 2017

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Diabetes, cancer, and metformin: connections of metabolism and cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Operating characteristics of a rank correlation test for publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Publication bias in clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical t

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Nonviral Risk Factors for Hepatocellular Carcinoma in a Low-Risk Population, the Non-Asians of Los Angeles County, California

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Role of AMP-activated protein kinase in mechanism of metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Functional role of peroxisome-proliferator-activated receptor γ in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Glucose-lowering therapies and cancer risk: the trials and tribulations of trials and observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Statins and risk reduction in hepatocellular carcinoma: fact or fiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.5

21 January 2018

Identifiers

DOI

10.1038/AJG.2013.5

1 reference

28 August 2017

1 reference